The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
U.K. guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis in adults 2016
Open accessAbstract
The overall objective of the guidelines is to provide up‐to‐date, evidence‐based recommendations for the diagnosis and management of the full spectrum of Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and SJS–TEN overlap in adults during the acute phase of the disease. The document aims to: (i) offer an appraisal of all relevant literature up to February 2016, focusing on any key developments; (ii) address important, practical clinical questions relating to the primary guideline objective, i.e. accurate diagnosis and identification of cases and suitable treatment; (iii) provide guideline recommendations; and (iv) discuss areas of uncertainty, potential developments and future directions SJS/TEN is rare and few healthcare professionals are confident in the recognition and management of the disorder. There is widely divergent practice among different specialities and healthcare settings, and limited information on outcomes. These guidelines aim to provide recommendations on the diagnosis and management of SJS/TEN, to inform clinical decision‐making and, when justified by evidence, to standardize practice. The breadth of this document should be sufficient to assist clinicians of all relevant specialities in the management of patients with SJS/TEN. The recommendations will also inform pathways of care to optimize healthcare delivery and highlight key areas of uncertainty for future research. In these guidelines, the term SJS/TEN encompasses the full spectrum of the disease, i.e. SJS, TEN and SJS–TEN overlap (see section section 10 for clinical definition of the separate entities). The guideline is presented as a detailed review with highlighted recommendations for practical use (see section section 64), in addition to the development of a new patient information leaflet [available on the British Association of Dermatologists’ (BAD) website, www.bad.org.uk]. Unless otherwise specified, recommendations apply to all forms of the disease. This guideline does not cover paediatric patients. An addendum to this guideline addressing the needs of paediatric patients with SJS/TEN is planned. The evidence for treatment of children differs from that of adult patients, and will be considered separately. The management of long‐term sequelae of SJS/TEN is not considered in this document. The guideline development group (GDG) consisted of consultant dermatologists (D.C., S.A.W., H.Y.L., J.S., C.B.B., M.R.A.‐J., K.M.T.W., G.A.E.W., C.H.S.), including oral (J.S.) and urogenital specialists (S.A.W., C.B.B.), a histopathologist (M.P.), burns/plastic surgeon specialists (P.D., G.W., M.S.), a burns anaesthestist (R.V.M.), intensive care specialists (A.V., R.V.M.), an ophthalmologist (J.K.G.D.), a dermatological clinical nurse specialist (D.B.) and a patient (P.W.). The draft document went out for consultation to the BAD membership, British Dermatological Nursing Group, Primary Care Dermatological Society, British Burn Association, British Association of Plastic, Reconstructive and Aesthetic Surgeons, Royal College of Ophthalmologists, Association of Anaesthetists of Great Britain and Ireland, Intensive Care Society and SJS Awareness U.K. The comments received were actively considered by the GDG. Following further review, the amended draft was recirculated to the stakeholders for comments and the finalized version peer‐reviewed by the Clinical Standards Unit of the BAD (made up of the Therapy & Guidelines Subcommittee) prior to publication. This set of guidelines has been developed using the BAD's recommended methodology,1 and with reference to the Appraisal of Guidelines Research and Evaluation (AGREE II) instrument (www.agreetrust.org).2 Recommendations were developed for implementation in the National Health Service using a process of considered judgement based on the evidence. A series of specific questions was developed within the scope of the guideline; for each question, PubMed, MEDLINE and Embase, and the Cochrane Library were searched for meta‐analyses, randomized and nonrandomized controlled clinical trials, open studies and case series to February 2016. The literature was searched for evidence to address the questions. The search terms and strategies are detailed online (Data S1; see Supporting Information). Additional relevant references were also isolated from citations in the reviewed literature, as well as specific targeted searches for hypersensitivity testing, causative drugs, diagnostic and prognostic indicators, topical treatments, oral/mouth, growth factors and granulocyte colony‐stimulating factor (G‐CSF), and analgesia. The lead authors screened the identified titles, and those relevant for first‐round inclusion were selected for further scrutiny. All co‐authors then reviewed the abstracts for the shortlisted references and the full papers of relevant material were obtained; disagreements in the final selections were resolved by discussion with the entire GDG. In section section 47, active inte
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AGREE II: advancing guideline development, reporting and evaluation in health care
Brouwers, M. C., Kho, M. E., Browman, G. P., Burgers, J. S., Cluzeau, F., Feder, G., Fervers, B., Graham, I. D., Grimshaw, J., Hanna, S. E., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.090449 · Cited by 3,790
ESPEN guidelines on parenteral nutrition: intensive care
Singer, P., Berger, M. M., Van den Berghe, G., Biolo, G., Calder, P., Forbes, A., Griffiths, R., Kreyman, G., Leverve, X., & Pichard, C. (2009) · Clinical Nutrition · doi:10.1016/j.clnu.2009.04.024 · Cited by 1,907
Bastuji‐Garin, S. (1993) · Archives of Dermatology · doi:10.1001/archderm.129.1.92 · Cited by 1,697
Severe Adverse Cutaneous Reactions to Drugs
Roujeau, J. C., & Stern, R. S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311906 · Cited by 1,571
Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal Necrolysis
Roujeau, J.-C., Kelly, J. P., Naldi, L., Rzany, B., Stern, R. S., Anderson, T., Auquier, A., Bastuji-Garin, S., Correia, O., Locati, F., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332404 · Cited by 1,465
ESPEN guidelines on enteral nutrition: intensive care
Kreymann, K. G., Berger, M. M., Deutz, N. E. P., Hiesmayr, M., Jolliet, P., Kazandjiev, G., Nitenberg, G., van den Berghe, G., Wernerman, J., Ebner, C., et al. (2006) · Clinical Nutrition · doi:10.1016/j.clnu.2006.01.021 · Cited by 1,366
SCORTEN: A Severity-of-Illness Score for Toxic Epidermal Necrolysis
Fouchard, N., Bertocchi, M., Roujeau, J.-C., Revuz, J., Wolkenstein, P., & Bastuji-Garin, S. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00061.x · Cited by 1,199
Mockenhaupt, M., Viboud, C., Dunant, A., Naldi, L., Halevy, S., Bavinck, J. N. B., Sidoroff, A., Schneck, J., Roujeau, J.-C., & Flahault, A. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701033 · Cited by 1,017
Inhibition of Toxic Epidermal Necrolysis by Blockade of CD95 with Human Intravenous Immunoglobulin
Viard, I., Wehrli, P., Bullani, R., Schneider, P., Holler, N., Salomon, D., Hunziker, T., Saurat, J.-H., Tschopp, J., & French, L. E. (1998) · Science · doi:10.1126/science.282.5388.490 · Cited by 1,005
Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin
(1999) · Transfusion Medicine Reviews · doi:10.1016/s0887-7963(99)80071-6 · Cited by 869
Chung, W.-H., Hung, S.-I., Yang, J.-Y., Su, S.-C., Huang, S.-P., Wei, C.-Y., Chin, S.-W., Chiou, C.-C., Chu, S.-C., Ho, H.-C., et al. (2008) · Nature Medicine · doi:10.1038/nm.1884 · Cited by 840
Sassolas, B., Haddad, C., Mockenhaupt, M., Dunant, A., Liss, Y., Bork, K., Haustein, U. F., Vieluf, D., Roujeau, J. C., & Le Louet, H. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.252 · Cited by 758
Support of the metabolic response to burn injury
Herndon, D. N., & Tompkins, R. G. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16360-5 · Cited by 532
Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis
Wolkenstein, P., Latarjet, J., Roujeau, J.-C., Duguet, C., Boudeau, S., Vaillant, L., Maignan, M., Schuhmacher, M.-H., Milpied, B., Pilorget, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02197-7 · Cited by 428
Toxic epidermal necrolysis: Effector cells are drug-specific cytotoxic T cells
Nassif, A., Bensussan, A., Boumsell, L., Deniaud, A., Moslehi, H., Wolkenstein, P., Bagot, M., & Roujeau, J.-C. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.07.047 · Cited by 412
Barbaud, A., Collet, E., Milpied, B., Assier, H., Staumont, D., Avenel-Audran, M., Grange, A., Amarger, S., Girardin, P., Guinnepain, M.-T., et al. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12125 · Cited by 398
Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients
Revuz, J. E. (1987) · Archives of Dermatology · doi:10.1001/archderm.123.9.1160 · Cited by 395
Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985
Roujeau, J. (1990) · Archives of Dermatology · doi:10.1001/archderm.126.1.37 · Cited by 391
The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity
NYFELER, B., & PICHLER, W. J. (1997) · Clinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy · doi:10.1046/j.1365-2222.1997.d01-495.x · Cited by 387
Toxic epidermal necrolysis (Lyell syndrome)
Roujeau, J.-C., Chosidow, O., Saiag, P., & Guillaume, J.-C. (1990) · Journal of the American Academy of Dermatology · doi:10.1016/0190-9622(90)70333-d · Cited by 383
Bachot, N., Revuz, J., & Roujeau, J.-C. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.1.33 · Cited by 380
Rzany, B., Mockenhaupt, M., Baur, S., Schröder, W., Stocker, U., Mueller, J., Holländer, N., Bruppacher, R., & Schöpf, E. (1996) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(96)00035-2 · Cited by 355
Prins, C., Kerdel, F. A., Padilla, R. S., Hunziker, T., Chimenti, S., Viard, I., Mauri, D. N., Flynn, K., Trent, J., Margolis, D. J., et al. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.1.26 · Cited by 325
Schwartz, R. A., McDonough, P. H., & Lee, B. W. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.05.003 · Cited by 316
Toxic Epidermal Necrolysis (Lyell Syndrome): Incidence and Drug Etiology in France, 1981-1985
Roujeau, J.-C. (1990) · Archives of Dermatology · doi:10.1001/archderm.1990.01670250043005 · Cited by 316
Palmieri, T. L., Greenhalgh, D. G., Saffle, J. R., Spence, R. J., Peck, M. D., Jeng, J. C., Mozingo, D. W., Yowler, C. J., Sheridan, R. L., Ahrenholz, D. H., et al. (2002) · The Journal of Burn Care & Rehabilitation · doi:10.1097/00004630-200203000-00004 · Cited by 308
Power, W. J., Ghoraishi, M., Merayo-Lloves, J., Neves, R. A., & Foster, C. S. (1995) · Ophthalmology · doi:10.1016/s0161-6420(95)30811-1 · Cited by 290
Kano, Y., Hirahara, K., Mitsuyama, Y., Takahashi, R., & Shiohara, T. (2007) · Allergy · doi:10.1111/j.1398-9995.2007.01553.x · Cited by 276
Valeyrie-Allanore, L., Wolkenstein, P., Brochard, L., Ortonne, N., Maître, B., Revuz, J., Bagot, M., & Roujeau, J. C. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2010.09863.x · Cited by 274
The Culprit Drugs in 87 Cases of Toxic Epidermal Necrolysis (Lyell's Syndrome)
Guillaume, J. C. (1987) · Archives of Dermatology · doi:10.1001/archderm.123.9.1166 · Cited by 257
Guégan, S., Bastuji-Garin, S., Poszepczynska-Guigné, E., Roujeau, J.-C., & Revuz, J. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700068 · Cited by 253
Huang, Y.-C., Li, Y.-C., & Chen, T.-J. (2012) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2012.10965.x · Cited by 223
Treatment of Toxic Epidermal Necrolysis with Cyclosporin A
Ar??valo, J. M., Lorente, J. A., Gonz??lez-Herrada, C., & Jim??nez-Reyes, J. (2000) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/00005373-200003000-00017 · Cited by 212
T cell involvement in cutaneous drug eruptions
Hari, Y., Frutig‐Schnyder, K., Hurni, M., Yawalkar, N., Zanni, M. P., Schnyder, B., Kappeler, A., Von Greyerz, S., Braathen, L. R., & Pichler, W. J. (2001) · Clinical & Experimental Allergy · doi:10.1046/j.1365-2222.2001.01164.x · Cited by 197
Kirchhof, M. G., Miliszewski, M. A., Sikora, S., Papp, A., & Dutz, J. P. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.07.016 · Cited by 191
Etanercept therapy for toxic epidermal necrolysis
Paradisi, A., Abeni, D., Bergamo, F., Ricci, F., Didona, D., & Didona, B. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.04.044 · Cited by 184
Successful Treatment of Stevens-Johnson Syndrome with Steroid Pulse Therapy at Disease Onset
Araki, Y., Sotozono, C., Inatomi, T., Ueta, M., Yokoi, N., Ueda, E., Kishimoto, S., & Kinoshita, S. (2009) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2008.12.040 · Cited by 152
Detection and quantification of drug‐specific T cells in penicillin allergy
Rozières, A., Hennino, A., Rodet, K., Gutowski, M. C., Gunera-Saad, N., Bérard, F., Cozon, G. J. N., Bienvenu, J., & Nicolas, J. (2009) · Allergy · doi:10.1111/j.1398-9995.2008.01674.x · Cited by 147
Viard, I., Gaide, O., Jankovic, D. L., Feldmeyer, L., Kerl, K., Pickard, C., Roques, S., Friedmann, P. S., Contassot, E., & French, L. E. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.330 · Cited by 143
Porębski, G., Pecaric-Petkovic, T., Groux‐Keller, M., Bosak, M., Kawabata, T. T., & Pichler, W. J. (2013) · Clinical & Experimental Allergy · doi:10.1111/cea.12145 · Cited by 139
Gregory, D. G. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.01.046 · Cited by 134
Immune Mechanisms in Drug Allergy
Roujeau, J. (2006) · Allergology International · doi:10.2332/allergolint.55.27 · Cited by 127
Shay, E., Kheirkhah, A., Liang, L., Sheha, H., Gregory, D. G., & Tseng, S. C. G. (2009) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2009.03.004 · Cited by 115
Shammas, M. C., Lai, E. C., Sarkar, J. S., Yang, J. H., Starr, C. E., & Sippel, K. C. (2009) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2009.08.040 · Cited by 111
Lee, H. Y., Lim, Y. L., Thirumoorthy, T., et al. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12607 · Cited by 110
Self-citationBacteremia in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
de Prost, N., Oro, S., Duong, T. A., Valeyrie‐Allanore, L., Legrand, P., Wolkenstein, P., Brochard, L. J., Brun‐Buisson, C., & Roujeau, J. (2010) · Medicine · doi:10.1097/md.0b013e3181ca4290 · Cited by 106
Tripathi, A., Ditto, A. M., Grammer, L. C., Greenberger, P. A., McGrath, K. G., Zeiss, C. R., & Patterson, R. (2000) · Allergy and Asthma Proceedings · doi:10.2500/108854100778250914 · Cited by 105
Toxic epidermal necrolysis: Five years of treatment experience from a burn unit
Firoz, B., HENNING, J. S., Zarzabal, L. A., et al. (2012) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2011.12.014 · Cited by 100
Lochmatter, P., Beeler, A., Kawabata, T. T., Gerber, B. O., & Pichler, W. J. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.01985.x · Cited by 100
Cartotto, R., Mayich, M., Nickerson, D., & Gómez, M. (2008) · Journal of Burn Care & Research · doi:10.1097/bcr.0b013e31815f3865 · Cited by 97
Zawodniak, A., Lochmatter, P., Yerly, D., Kawabata, T. T., Lerch, M., Yawalkar, N., & Pichler, W. J. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.02180.x · Cited by 89
Narita, Y. M., Hirahara, K., Mizukawa, Y., et al. (2011) · The Journal of Dermatology · doi:10.1111/j.1346-8138.2010.01154.x · Cited by 76
Lymphocyte Transformation Test in Drug-Induced Toxic Epidermal Necrolysis
Roujeau, J., Albengres, E., Moritz, S., Piacentino, A., Cuny, M., Revuz, J. E., & Touraine, R. (2009) · International Archives of Allergy and Applied Immunology · doi:10.1159/000233856 · Cited by 74
Sachs, B., Erdmann, S., Malte Baron, J., Neis, M., Al Masaoudi, T., & Merk, H. F. (2002) · Clinical & Experimental Allergy · doi:10.1046/j.1365-2222.2002.01382.x · Cited by 74
Chen, J., Wang, B., Zeng, Y., & Xu, H. (2010) · PubMed · doi:10.1684/ejd.2010.1077 · Cited by 68
What Are the Fluid Requirements in Toxic Epidermal Necrolysis?
Shiga, S. A., & Cartotto, R. (2010) · Journal of Burn Care & Research · doi:10.1097/bcr.0b013e3181cb8cb8 · Cited by 62
T-cell reactions to drugs in distinct clinical manifestations of drug allergy.
Neukomm, C. B., Yawalkar, N., Helbling, A., et al. (2001) · PubMed · Cited by 59
Mycoplasma pneumoniae‐associated mucositis – case report and systematic review of literature
Vujic, I., Shroff, A., Grzelka, M., Posch, C., Itzinger-Monshi, B., Sanlorenzo, M., Ortiz‐Urda, S., & Rappersberger, K. (2014) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12392 · Cited by 56
Prevention of vulvovaginal sequelae in stevens-johnson syndrome and toxic epidermal necrolysis.
Kaser, D. J., Reichman, D. E., & Laufer, M. R. (2011) · PubMed Central · Cited by 46
Resuscitation of thermal injuries in the United Kingdom and Ireland
Baker, R., Akhavani, M., & Jallali, N. (2007) · Journal of Plastic Reconstructive & Aesthetic Surgery · doi:10.1016/j.bjps.2006.09.003 · Cited by 46
Chapman, A. D. S., Williams, G., Soni, N., & Bunker, C. B. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09585.x · Cited by 41
Self-citationToxic epidermal necrolysis and Steven Johnson syndrome: 11-years experience and outcome.
Gravante, G. G., Delogu, D., Marianetti, M., Trombetta, M., Esposito, G., & Montone, A. (2007) · PubMed · Cited by 35
Prevention and treatment of stress ulcers in critically ill patients.
Yang, Y., & Lewis, J. D. (2003) · PubMed · Cited by 33
Halevy, S., & Grossman, N. (2008) · PubMed · Cited by 28
Prompt versus delayed amniotic membrane application in a patient with acute Stevens-Johnson syndrome
Ciralsky, J. B., & Sippel, K. C. (2013) · Clinical ophthalmology · doi:10.2147/opth.s45054 · Cited by 22
Lacy, J. A. (1991) · Nutrition in Clinical Practice · doi:10.1177/011542659100600118 · Cited by 10
Cited by
Severe cutaneous adverse reactions to drugs
Duong, T. A., Valeyrie-Allanore, L., Wolkenstein, P., & Chosidow, O. (2017) · The Lancet · doi:10.1016/s0140-6736(16)30378-6 · Cited by 445
Current perspectives on severe drug eruption
Zhang, J., Lei, Z., Xu, C., Zhao, J., & Kang, X. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08859-0 · Cited by 60
Metadata
- Authors
- Creamer, D., Walsh, S. A., Dziewulski, P., Exton, L. S., Lee, H. Y., Dart, J. K. G., Setterfield, J., Bunker, C. B., Ardern‐Jones, M. R., Watson, K. M. T., Wong, G. A. E., Philippidou, M., Vercueil, A., Martin, R. V., Williams, G., Shah, M., Brown, D., Williams, P., Mohd Mustapa, M. F., Smith, C. H., McHenry, P. M., Hughes, J. R., Griffiths, M., Gibbon, K., McDonagh, A. J., Buckley, D. A., Nasr, I., Swale, V. J., Duarte Williamson, C. E., Levell, N. J., Leslie, T., Mallon, E., Wakelin, S., Ungureanu, S., Hunasehally, P., Cork, M., Towers, K., Donnelly, J., Saunders, C., & Brain, A. G.
- Venue
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-06
- Volume
- 174
- Issue
- 6
- Pages
- 1194-1227
- ISSN
- 0007-0963 (ISSN-L)
- 1365-2133
- OpenAlex
- W2419735139
- Cited by
- 277
- References
- 66
- FWCI
- 19.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.